DCGI approves Favipiravir for treating COVID-19

The drugs controller general of India (DGCI) granted approval to Glenmark Pharmaceuticals to manufacture and market oral antiviral drug Favipiravir to treat mild and moderate COVID-19 cases in India. The drug will be marketed under the brand name ‘FabiFlu’. It is known to prevent the virus from replication. In Japan, the drug is sold under brand name Avigan to treat influenza.